**Outpatient Remdesivir at Children’s Nebraska**

March 2024

Veklury®(remdesivir) is FDA approved for treatment of COVID-19 in adults and pediatric patients (weighing at least 1.5kg) who are: 1) hospitalized or 2) non-hospitalized and have mild to moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

If you would like a patient to receive outpatient remdesivir through the infusion center at Children’s Nebraska follow these steps:

1. Patient must be within 7 days of symptom onset
2. Determine insurance coverage and cost by sending email to [\_authorizations@childrensnebraska.org](mailto:_authorizations@childrensnebraska.org) and [estimaterequest@childrensnebraska.org](mailto:estimaterequest@childrensnebraska.org) , mark URGENT, and include all the information below:

* Patient name
* DOB
* MRN
* Insurance information
* Exact Dose, frequency, and duration---- (usually: remdesivir 5mg/kg (max dose 200mg) on day 1 then 2.5mg/kg (max dose 100mg) daily for 2 additional days
* Providers contact information or designee

1. Ensure family knows the treatment is for 3 consecutive days, given IV, side effects, cost, etc. prior to having family schedule appointments
2. Once above steps have been completed have family contact ambulatory scheduling at 402-955-6799 to schedule the 3 consecutive appointments
3. Once patients arrive for remdesivir appointments, orders will be entered by the infusion center staff for administration of the drug.

For families who need additional financial support providers can also contact Gilead patient assistance program <https://www.gileadadvancingaccess.com/hcp/covid-19>